Literature DB >> 2235121

Protein metabolism in phenylketonuria and Lesch-Nyhan syndrome.

G N Thompson1, P J Pacy, R W Watts, D Halliday.   

Abstract

Animal and in vitro studies have implicated decreased protein synthesis in the pathogenesis of tissue damage in phenylketonuria (PKU) and of growth failure in Lesch-Nyhan syndrome. Protein turnover was measured in vivo in ten young adult subjects with classical PKU, two subjects with hyperphenylalaninemia, and three children with Lesch-Nyhan syndrome using techniques based on continuous infusions of [13C]leucine and, in Lesch-Nyhan subjects, [2H5]phenylalanine. The PKU subjects had various degrees of dietary phenylalanine restriction and plasma phenylalanine levels at the time of study ranged from 450-1540 mumol/L (mean 1106). Plasma phenylalanine in the two hyperphenylalaninemic subjects was 533 and 402 mumol/L. Rates of protein synthesis in all PKU subjects (mean 3.71 g/kg/24 h, range 2.68-5.10, [13C]leucine as tracer) were in a range similar to or above control values (mean 2.97, range 2.78-3.22, n = 6), as were rates of protein catabolism (PKU mean 4.23 g/kg/24 h, range 3.15-5.45; controls 3.64, 3.50-3.91). Protein turnover values in hyperphenylalaninemia were also similar to those in controls. With [13C]leucine as tracer, both mean protein synthesis and catabolism values in Lesch-Nyhan subjects (mean 4.80 and 5.64 g/kg/24 h, respectively) were higher than values in control children matched for protein intake (synthesis 4.32 +/- 0.74 (SD) and catabolism 4.85 +/- 0.57 (g/kg/24 h, n = 5). Similar results were obtained in Lesch-Nyhan subjects using [2H5]phenylalanine as tracer. These results suggest that protein turnover is not decreased in either PKU or Lesch-Nyhan syndrome. This conclusion is inconsistent with the hypothesis that tissue damage in PKU results from impaired protein synthesis.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2235121     DOI: 10.1203/00006450-199009000-00019

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  6 in total

1.  Modelling the phenylalanine blood level response during treatment of phenylketonuria.

Authors:  U Langenbeck; J Zschocke; U Wendel; V Hönig
Journal:  J Inherit Metab Dis       Date:  2001-12       Impact factor: 4.982

2.  Whole body protein metabolism in children with cancer.

Authors:  S E Daley; A D Pearson; A W Craft; J Kernahan; R A Wyllie; L Price; C Brock; C Hetherington; D Halliday; K Bartlett
Journal:  Arch Dis Child       Date:  1996-10       Impact factor: 3.791

3.  Lesch-Nyhan syndrome and its pathogenesis: normal nicotinamide-adenine dinucleotide but reduced ATP concentrations that correlate with reduced poly(ADP-ribose) synthetase activity in HPRT-deficient lymphoblasts.

Authors:  G M McCreanor; R A Harkness
Journal:  J Inherit Metab Dis       Date:  1995       Impact factor: 4.982

4.  Amino Acid Plasma Profiles from a Prolonged-Release Protein Substitute for Phenylketonuria: A Randomized, Single-Dose, Four-Way Crossover Trial in Healthy Volunteers.

Authors:  Mika Scheinin; Anna Barassi; Jouni Junnila; Zsófia Lovró; Giorgio Reiner; Essi Sarkkinen; Anita MacDonald
Journal:  Nutrients       Date:  2020-06-02       Impact factor: 5.717

5.  In Vivo Metabolic Responses to Different Formulations of Amino Acid Mixtures for the Treatment of Phenylketonuria (PKU).

Authors:  Nadia Giarratana; Luciana Giardino; Andrea Bighinati; Giorgio Reiner; Júlio César Rocha
Journal:  Int J Mol Sci       Date:  2022-02-17       Impact factor: 5.923

6.  Comparison of Glycomacropeptide with Phenylalanine Free-Synthetic Amino Acids in Test Meals to PKU Patients: No Significant Differences in Biomarkers, Including Plasma Phe Levels.

Authors:  Kirsten K Ahring; Allan M Lund; Erik Jensen; Thomas G Jensen; Karen Brøndum-Nielsen; Michael Pedersen; Allan Bardow; Jens Juul Holst; Jens F Rehfeld; Lisbeth B Møller
Journal:  J Nutr Metab       Date:  2018-01-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.